key: cord-0483385-4sxnpjzd
authors: MacMahon, M'eabh; Hwang, Woochang; Yim, Soorin; MacMahon, Eoghan; Abraham, Alexandre; Barton, Justin; Tharmakulasingam, Mukunthan; Bilokon, Paul; Gaddi, Vasanthi Priyadarshini; Han, Namshik
title: Identification and validation of Triamcinolone and Gallopamil as treatments for early COVID-19 via an in silico repurposing pipeline
date: 2021-07-05
journal: nan
DOI: nan
sha: 1163804387afe4210efbbbf8564a17b123ee3512
doc_id: 483385
cord_uid: 4sxnpjzd

SARS-CoV-2, the causative virus of COVID-19 continues to cause an ongoing global pandemic. Therapeutics are still needed to treat mild and severe COVID-19. Drug repurposing provides an opportunity to deploy drugs for COVID-19 more rapidly than developing novel therapeutics. Some existing drugs have shown promise for treating COVID-19 in clinical trials. This in silico study uses structural similarity to clinical trial drugs to identify two drugs with potential applications to treat early COVID-19. We apply in silico validation to suggest a possible mechanism of action for both. Triamcinolone is a corticosteroid structurally similar to Dexamethasone. Gallopamil is a calcium channel blocker structurally similar to Verapamil. We propose that both these drugs could be useful to treat early COVID-19 infection due to the proximity of their targets within a SARS-CoV-2-induced protein-protein interaction network to kinases active in early infection, and the APOA1 protein which is linked to the spread of COVID-19.

The novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes Coronavirus disease 2019 (COVID- 19) , was first identified in Wuhan in December 2019 and by June 2021 had spread to 192 countries or regions and infected over 165 million people, killing more than 3 million people 1 . COVID-19 infection has a wide spectrum of symptoms. Those with mild infections may be asymptomatic, have anosmia 2 or mild respiratory symptoms 3 , whereas severe infections lead to acute respiratory distress syndrome (ARDS) and potentially death 4 .

Treatments are urgently needed to reduce the severity and mortality rate of COVID- 19 . However development of a novel therapeutic takes many years 5 and has high attrition rates, often due to safety and toxicity 6 . Drug repurposing is the repositioning of existing 3 approved or investigational drugs to therapeutic uses beyond the scope of the original medical indication 7 . This approach offers de-risked possibilities to identify safe, effective treatments faster and more economically than novel drug development 8 .

Despite impressive progress in the past year, there is still a need for COVID -19 treatments. WHO recommends Dexamethasone for severe COVID-19 but also advises against its use in non-severe COVID-19 patients 9 . In the US, the FDA approved Veklury (Remdesivir) for patients who are hospitalised with COVID-19 10 . Although there are no approved treatments for mild COVID-19, emergency use authorisation has been granted for several monoclonal antibodies on mild-to-moderate patients, but only for those who are at risk of severe disease, and only approved via intravenous administration 11 . Monoclonal antibodies are expensive 12 with one dose of Bamlanivimab (which has emergency use authorisation) costing $1,250 per vial 13 . Chemical structure similarity is based on the concept that structurally similar molecules often share similar biological function, and is a concept frequently used in drug discovery 14 . Our in silico approach predicts potential candidates for repurposing to treat COVID-19 based on structural similarity to drugs already in clinical trials (CTDs) for COVID-19. CTDs were used as a starting point as there are few FDA-approved drugs for COVID-19. On the other hand, there are sufficient number of CTDs that are assumed to have some hypothesised utility in COVID-19, and at least one has been approved.

Treatments during the early stages of COVID-19 infection, which might also prevent the progression from mild to severe disease, would be particularly useful to relieve the burden on hospitals. We hypothesise that drugs which affect viral replication pathways could be used to treat early COVID-19, preventing hospitalisation.

Identification of chemical structure similarity 4 To identify drugs which could be safely and rapidly deployed to treat COVID-19, we used the ChEMBL API to computationally predict structurally similar drugs (SSDs) to drugs in clinical trials for COVID-19 (C19-CTDs); this was based on the Tanimoto coefficient (Tc), a similarity measure widely used in molecular fingerprint comparison 15 . There were 7,682 compounds in clinical trials for any indication at Phase II or higher (including approved). Figure 1 outlines the workflow we used to identify which of these are similar to C19-CTDs, and the filtering steps to identify those with potential for treating early-stage COVID-19. Among these 7,682 compounds, 101 compounds were determined to have structural similarity to 185 C19-CTDs, with a Tanimoto coefficient > 70 ( Figure 1 ). Figure 

To select the most promising SSDs for the treatment of early-stage COVID-19, we applied multiple stages of filtering ( Figure 1 ). The rationale for our approach is to expand the array of drugs which are being investigated and used to treat COVID-19 during this pandemic.

Although we selected SSDs due to structural similarity to C19-CTDs, we wanted to avoid focusing on drugs which are already being heavily studied for utility in treating COVID-19.

For this reason, we retained only SSDs which do not have the same utility as the C19-CTD which they were predicted from. We removed SSDs that target the same proteins, or which we predicted to impact the same biological pathways as their corresponding C19-CTDs, retaining only those which will elicit different therapeutic effects.

In the first stage of filtering, the list of SSDs was cleaned to remove any drugs which were effectively duplicated ( Figure 1 ). For instance, Taribavirin and Taribavirin hydrochloride were both identified as being similar to Ribavirin (similarity score 76.2). However, since

Taribavirin hydrochloride is the acid salt of Taribavirin, and once solubilized in the body (at approximately pH 7.4), both structures will exist in the same deprotonated form and have the same behaviour, these were considered as effective duplicates and the acid salt was removed from the filtered list of SSDs. After the removal of effective duplicates, 78 SSDs remained.

Secondly, we excluded antineoplastic agents from our list of SSDs. Since these cancer drugs may cause severe adverse drug reactions in patients [16] [17] [18] , we concluded that they would not be suitable to treat mild COVID-19 infections. We eliminated five antineoplastic agents, which have ATC code L01, due to this toxicity issue. This reduced the list to 73 SSDs.

Thirdly, we eliminated any SSD with exactly the same target proteins as its corresponding C19-CTD as we reasoned that it would be unlikely for the two drugs to have different therapeutic effects. After this step, there were 28 SSDs. Further filtering was done to ensure that retained SSDs were targeting enough different proteins (and sufficiently 6 separated on a COVID-19 protein-protein network) from their corresponding C19-CTD so as to be sufficiently biologically distinct.

We used the SARS-CoV-2-induced protein (SIP) network at 24 hours generated by

Han et al 19 as the base network to investigate this in the context of COVID-19. This network contains the directly interacting proteins (DIP) of SARS-CoV-2 identified by mass spectrometry 20 , differentially expressed proteins (DEP) after SARS-CoV-2 infection identified by mass spectrometry 21 , and a layer of connections between the two built using known protein-protein interaction (PPI) data as described by Han et al. 19 . We used the 24 hour SIP network because the key proteins are more enriched in viral replication and there are a significantly increased number of protein-protein interactions (PPI) in RNA-or viralreplication-related pathways 19 , which we wanted to examine impact upon.

If the average distance between the targets of any SSD and its corresponding C19-CTD in the SIP 24-hour network 19 was less than 1, the drug was filtered out (see Methods).

Through this analysis, we identified 17 (21%) SSDs predicted from 11 C19-CTDs.

To establish the Mechanism of Action (MoA) of the 17 identified drugs, we characterised the pathways that are targeted by each drug. The purpose of the MoA analysis was first to discover SSDs which have different MoA to their corresponding C19-CTD and to better understand whether these identified SSDs would be useful in treating early-stage COVID-19.

An initial pathway enrichment test performed on the target proteins of all 28 drugs (17 SSDs and 11 C19-CTDs) which were found in the SIP 24-hour network identified a set of 488 biological pathways. As a measure of the accuracy of this enrichment, we then calculated the precision and recall of the enrichment test to produce an F1 score. The F1 scores were calculated for each drug-pathway association, and we generated an F1 score matrix for all 28 drugs, including an F1 score for 488 pathways.

The unsupervised training of a Self-Organizing Map (SOM) with the F1 score matrix generated 28 SOM component plane heatmaps (Supplementary Figure 1) . Each heatmap 7 represents the pattern of associated pathways for a drug and each hexagon in the heatmap has unique pathways which have the same position across all heatmaps (corresponding to drugs). As each heatmap in the SOM results maintains the same position for each hexagon, this allows direct visual comparison between pathways affected by each drug. To exclude SSDs with a similar drug-pathway association as their C19-CTD, we calculated the correlation coefficient (r) between SOM heatmap values for each pair. We excluded SSDs which were correlated with their corresponding SSD (r > 0.5) to narrow our focus on SSDs which had different associated pathways than their corresponding C19-CTD.

This identified 12 SSDs that were similar to eight C19-CTDs ( Figure 3A ). The SSDs identified were Triamcinolone and Beclomethasone (which are similar to Dexamethasone),

Omega-3-Carboxylic Acids (which is similar to Icosapent), Beta Carotene (which is similar to Isotretinoin), Dextrothyroxine (which is similar to Liothyronine), Xylitol (which is similar to Mannitol), Clinidipine (which is similar to Nimodipine), Gallopamil (which is similar to Verapamil) and four SSDs similar to Zinc Sulfate. These SSDs were filtered to ensure that they target different proteins and different pathways to their corresponding C19-CTDs.

To assess whether any of our predicted drugs would be useful in treating early COVID-19

infection before it develops into severe disease, we determined which SSDs impacted on pathways related to viral replication. Viruses replicate by hijacking the processes of the host cell; they cannot replicate by themselves. From the SOM analysis, the pathways associated with each SSD had been established (Supplementary Figure 2) . The 488 pathways assigned to hexagons in the SOM heatmap were clustered using a unified distance matrix (U-matrix, Figure 3B ) that captures the distribution of the trained artificial neurons in the data space ( Figure 3C ). The SOM also provided the clustering information based on the U-matrix and number of hits (pathways) per hexagon (neuron) ( Figure 3D ). In addition, we calculated the Davies-Bouldin index (DBI) that provides the optimal number of clusters in k-means clustering ( Figure 3E ). Finally, the 448 pathways were classified into 10 pathway clusters 8 ( Figure 3F , Supplementary Table 1 ). We used this information to identify which of the remaining SSDs were impacting on pathways involved with viral replication. These are also highlighted in Figure 3F . We reasoned that viral replication-related drugs may be more useful for the treatment of early-stage disease, while drugs whose targets are linked with immune-response-associated pathways may be better suited for later-stage COVID-19

infection.

As an example of this approach, we present the two SSDs which were structurally similar to Dexamethasone. The correlation coefficient between Dexamethasone and both SSDs (Beclomethasone and Triamcinolone) was lower than 0.5, so both were sufficiently different from Dexamethasone to be considered promising drug candidates for expanding the approach to COVID-19 treatments ( Figure 3A1 , Supplementary Table 2) . From

Beclomethasone's SOM heatmap, Beclomethasone was found to be associated with the ESR, Glycosylation, MAPK, AP-1 and PLA2 pathways ( Figure 3F ), and these associated pathways are predominantly related to the immune response. Triamcinolone on the other hand was found to be associated with the high-density lipoprotein (HDL) remodelling pathway ( Figure 3F ), a process which is reported to be strongly related to coronavirus replication 22,23 , so we studied Triamcinolone further as a potential treatment for early-stage COVID-19 infection.

Using the same approach, we also identified Gallopamil, Omega-3-Carboxylic Acids and Beta Carotene for treating COVID-19 at an early stage of infection. The SOM heatmaps for Gallopamil and Triamcinolone are highly similar ( Figure 3A1 and 3A7), and unsurprisingly

Gallopamil is also associated with HDL remodelling ( Figure 3F ). Omega-3-Carboxylic Acids is associated with fatty acid beta-oxidation, which is related to virus replication 24 . Beta

Carotene is associated with Retinoic acid (RA), which is also related to virus replication.

However, Omega-3-Carboxylic Acids and Beta Carotene were discontinued 25 , so further analysis into the potential in early COVID-19 was conducted on Triamcinolone and Gallopamil only. 9 

To validate the activity of Triamcinolone and Gallopamil on viral replication of SARS-CoV-2,

we performed in silico validation on their targets within SIP network at 24-hours after infection 19 . To establish if these drugs impact on processes occurring early in COVID-19

infection, we measured the proximity of the targets of each drug to a group of kinases that are active in the first 24-hour post infection with SARS-CoV-2. Bouhaddou et al. 26 Table 3) . As a control, we randomly selected the same number of proteins as the target protein plus one neighbour proteins of the HDL-remodelling pathway. Of the targets of the two drugs, ACE and SERPINA6 directly interacted with APOA1 in the SIP 24hour network. APOA1, which is a major transporter of HDL-cholesterol, has been linked to the spread of COVID-19 28 and is essential for HDL metabolism and remodelling 29 

In this study, we have taken an in silico approach to highlight two drugs that have structural similarity to drugs already in COVID-19 clinical trials but can be differentiated from these existing drugs. Importantly, these have a distinct mechanism of action related to virus replication, and we therefore propose they may be useful in treating early-stage COVID-19

patients.

Triamcinolone is a corticosteroid identified on the basis of its similarity to C19-CTD Dexamethasone, and is approved for the treatment of a range of inflammatory conditions including allergies, arthritis, asthma and skin problems. Results from the RECOVERY trial showed that Dexamethasone reduces death in COVID-19 patients by approximately onethird 30 . Triamcinolone inhibits nuclear factor kappa-B, which decreases the production of proinflammatory signals such as interleukin-6 (IL-6), interleukin-8, and monocyte chemoattractant protein-1 31 . IL-6 plays an important role in cytokine release syndrome 32 which is triggered in severe COVID-19 patients. Sustained elevation of IL-6 is also linked to 13 death in acute respiratory distress syndrome 33 (ARDS), the respiratory condition experienced by critical COVID-19 patients.

Here we propose utility for Triamcinolone treatment in early COVID-19 infection to prevent the early activity of the virus. This is based on the proximity of its targets to key COVID-19 proteins including direct interactions with: SARS-CoV-2 DIP and DEP proteins;

APOA1, which has been linked to the spread of COVID-19 28 ; as well as kinases which are active in early SARS-CoV-2 infection (e.g. PIK3CA, AKT1 and 5 MAPK proteins). The PI3K-AKT and MAPK signalling pathways are among those reported to be altered following SARS-CoV-2 viral infection. 34 Gallopamil is an L-type calcium channel blocker and an analogue of Verapamil. A study using natural language processing suggested calcium channel blockers were associated with decreased mortality in hospitalised patients with COVID-19 infection 35 .

Gallopamil is not yet approved for the treatment of any disease, although it has been trialled orally (Phase II) for severe asthma with no significant difference in adverse effects between patients receiving Gallopamil or placebo 36 . Gallopamil targets MME, which is a direct interactor of ACE2. Since ACE2 is a cellular entry point for SARS-CoV-2 into human cells 37 , this could be a possible mechanism through which Gallopamil may target SARS-CoV-2 viral replication. Additionally, Gallopamil also targets ACE, which directly interacts with the HDL remodelling pathway proteins APOA1, APOE and ALB, as well as kinases that are active in infection (AKT1, MAPK3, and MAPK1). This suggests Gallopamil may target similar pathways to Triamcinolone during early COVID-19 infection.

Our in silico approach is based on publicly available data from online databases such as STITCH 38 and ChEMBL 39 , and studies published in response to the pandemic 19, 20, 26, 27 . By combining this information, we have predicted two drugs that interact with key pathways and proteins involved in early COVID-19 infection, suggesting this is an effective approach to take in this pandemic. It is likely that further diseases of zoonotic origin will emerge in the future 40 , and we must be prepared to respond rapidly to future pandemic threats. This kind of 14 in silico approach allows for a quick and cost-effective approach to repurposing drugs, which could be deployed in such a situation. Phase II trials and could be quickly prioritised into COVID-19 trials. We conclude that both would be good candidates for further investigation in in vitro and in vivo models as well as clinical trials.

Resource availability

Further information and requests for resources and materials should be directed to and will be fulfilled by the lead contact, Namshik Han (nh417@cam.ac.uk)

This study used publicly available data from online databases and other research papers. 15 

Code used for this study is available at https://github.com/wchwang/COVID-19.HfH.

A list of COVID-19 clinical trial drugs (C19-CTDs) was obtained from DrugBank 41 , an online bioinformatics and chemoinformatics database that contains data on drugs and their targets.

The ChemMBL API for chemical structural similarity accepts input in the simplified molecular-input line-entry system (SMILES), an ascii string format for representing chemical structures 42 . For each C19-CTD, the structure in SMILES format was extracted from the DrugBank XML file. The ChEMBL API library (written in python) was used to obtain a list of structurally similar drugs (SSDs). The ChEMBL structural similarity tool uses the Tanimoto coefficient (Tc) to predict structural similarity.

The list of SSDs was refined to remove drugs which fell into several categories (Figure 2 . Phase I trials and have therefore been tested for safety in humans. Tc > 70 was used as a similarity cut off. For context, a threshold of 70-75 is typical for structure based screening 43 . 16 The list of SSDs was cleaned to remove effective duplicates that behave the same in the body despite of a slightly different chemical structure.

We 

Drug-target interaction information was collected from DrugBank(v 5.1) 44 and STITCH(v 5.0, confidence score > 0.8) 45 .

We define the distance d C (S, C) between S, the set of target proteins of a SSD, and C, the set of target proteins of a C19-CTD, as the shortest path length d(s, c) between all pairs of nodes s ∈ S and c ∈ C in the SIP 24-hour network 19 . Closest distance measure (equation (1)) was used to calculate the distance between a SSD's target to a C19-CTD's target in the SIP 24hour network because it showed the best performance in drug-drug relationship prediction in a study by Cheng et al 46 .

To identify key pathways that are significantly enriched in the proteins that are targeted by 28 SSDs and C19-CTDs, we conducted pathway enrichment analysis using R (v 3.5.2) package and gprofiler2 47 hierarchical structure among pathways. The lower hierarchy pathway is more specific than the higher hierarchy pathway. The parent pathway semantically includes its child pathways.

In the process of integrating the enriched pathways per drug, we used the lowest-possible hierarchy pathways to avoid the overlapping biological meaning among the hierarchical pathways.

Based on these identifications, a matrix containing F1 scores of the 28 drugs and the 488 key pathways was generated for drug-pathway association. The Reactome pathway enrichment analysis for the 28 drugs using gprofiler2 provides enrichment p-values, precision and recall information that were used to produce the F1 scores. The meaning of precision here is that the proportion of drug targets that are annotated to the pathway. The meaning of recall here is that the proportion of the pathway gene sets that the drug targets recover. Precision and recall were used to construct a matrix of F1 score (F1=2(precision x recall)/(precision + recall) from the pathway enrichment analysis.

To identify mechanism of action (MoA) for Triamcinolone and Gallopamil in COVID-19 we identified their relationships within the SIP 24-hour SARS-CoV-2 network. There are 14, 827 proteins and 528,969 interactions in this network. Bouhaddou et al 26 to these active kinases in the SIP network, we calculated the distance of each target to each kinase and took the average of these distances. To establish significance, we did a permutation test. Each drug had 3 targets in the network, so we randomly generated 10,000 groups of 3 proteins and calculated the average distance of these from the active kinases ( Figure 4A ). We used closest 5% distances as a cut off to establish significance. To visualise the target proteins interacting with these kinases and other key COVID-10 proteins, we plotted subnetworks using Virtualitics Immersive Platform 49 .

To validate the effects of two drugs indirectly, Triamcinolone and Gallopamil, we checked whether the target proteins of drugs are significantly changed between patients with moderate COVID-19 and patients with severe COVID-19 when the expression of these targets is compared to expression of random proteins. Arunnachalam et al. 27 provide Log2 fold change of gene expression between 4 COVID-19 moderate patients verse 12 COVID-19 severe patients. In Figure 4C boxplot, only the proteins belonging to the HDL remodelling pathway among the neighbour proteins of each of the drugs target proteins in SIP 24-hour network and randomly selected control proteins were compared. Among the target proteins and their neighbour proteins, the same number of proteins in the HDL remodelling pathway were randomly selected. This random choice was repeated 100 times to create control proteins. For example, if five of the target proteins and their neighbour proteins belong to the 19 HDL remodelling pathway, 500 proteins were randomly selected and made into control proteins. The Mann Whitney U test was performed to determine whether the expression two groups were significantly different between moderate and severe COVID-19 patients. 

COVID-19 Map

Anosmia and loss of smell in the era of covid-19

Mild or Moderate Covid-19

Risk factors for severity and mortality in adult COVID-19

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Drug repositioning: identifying and developing new uses for existing drugs

Drug repurposing: progress, challenges and recommendations

Clinical management of COVID-19

Know Your Treatment Options for COVID-19

Emergency Use Authorization

Pricing of monoclonal antibody therapies: higher if used for cancer?

Eli Lilly's COVID-19 mAb bamlanivimab potential cost effectiveness underscores payer support

Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery

Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?

Thyroid Dysfunction from Antineoplastic Agents

Pulmonary toxicity from novel antineoplastic agents

Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies (Pharmacology and Toxicology)

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Induction of Apoptosis and Subsequent Phagocytosis of Virus-Infected Cells As an Antiviral Mechanism

Induction of Apoptosis by the Severe Acute Respiratory Syndrome Coronavirus 7a Protein Is Dependent on Its Interaction with the Bcl-XL

Influence of cellular lipid content on influenza A virus replication

Drugs@FDA: FDA-Approved Drugs

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Triamcinolone. In StatPearls

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic

Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study

Cell entry mechanisms of SARS-CoV-2

STITCH: interaction networks of chemicals and proteins

The ChEMBL bioactivity database: an update

Emerging Pandemic Diseases: How We Got to COVID-19

DrugBank 5.0: a major update to the DrugBank database

SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules

Molecular interaction fingerprint approaches for GPCR drug discovery

DrugBank 5.0: a major update to the DrugBank database

Network-based prediction of drug combinations

G:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update)

Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap

Virtualitics: Make Smarter AI-Driven Decisions Virtualitics

The authors acknowledge Dataswift Hack from home hackathon for bringing them together on this project. We would like to thank Dr Becky Harris and Dr Alison Schuldt for useful discussions. 

MM is an employee of LifeArc. NH and WH are funded by LifeArc. NH is a co-founder of KURE.ai and an advisor at Biorelate, Promatix, and Standigm. All other authors declare that they have no competing interests.